Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01860586 · ClinicalTrials.gov registry record · NA
Eye Injections of Bevacizumab for Lowering Risk of Scar Tissue in the Retina and Repeated Retinal Detachment.
A NA study, sponsored by Wills Eye.
- Completed
- Registry status
- NA
- Development phase
- 20
- Enrollment target
NCT01860586 is a NA study that has completed, run by Wills Eye. The registered enrollment target is 20 participants.
The verdict
NCT01860586, a NA study, has completed, sponsored by Wills Eye.
- COMPLETED
- Registry status
- NA
- Development phase
- 20 participants
- Enrollment target
Study Summary
The purpose of this study is to examine the effects of a drug called bevacizumab (Avastin) on the rates of recurrent retinal detachment and scar tissue formation.
Interventions
- DRUG Bevacizumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2013-06 |
| Est. Completion | 2014-11 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01860586
The ClinicalTrials.gov registry entry for NCT01860586 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Wills Eye, which has 59 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Bevacizumab is the first listed.
NCT01860586 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01860586 about?
NCT01860586 is a clinical study titled "Eye Injections of Bevacizumab for Lowering Risk of Scar Tissue in the Retina and Repeated Retinal Detachment.". The purpose of this study is to examine the effects of a drug called bevacizumab (Avastin) on the rates of recurrent retinal detachment and scar tissue formation.
What is the current status of trial NCT01860586?
This trial is currently completed. It is a NA study. The enrollment target is 20 participants. The study started on 2013-06. Estimated completion is 2014-11.
What interventions are being tested in trial NCT01860586?
The interventions under investigation include: Bevacizumab (DRUG).
Who is sponsoring clinical trial NCT01860586?
This trial is sponsored by Wills Eye, which has 59 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.